Fracture Prevention Trial
2001
Effect of Parathyroid Hormone (1-34) on Fractures
In 1,637 postmenopausal women with prior vertebral fractures, teriparatide 20 or 40 µg daily reduced new vertebral and non-vertebral fractures compared with placebo.
Result
Primary endpoint: New vertebral fracture
Vertebral fracture 5 % vs 14 %; RR 0.35 (20 µg), −65 %. Non-vertebral fragility −53 %.
- Subtopic
- Teriparatide
- Design
- Double-blind RCT, median 21 mo (stopped early for rat osteosarcoma signal)
- Relevance
- Important: one of several pillars.
- Source
- Neer RM, et al. N Engl J Med. 2001;344(19):1434-1441.doi 10.1056/NEJM200105103441904
Discussion & critique
First anabolic agent for osteoporosis, reserved for very high fracture risk and mandates sequential antiresorptive therapy thereafter.